Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients with CLN2 Disease

Next Previous
X
Search
Trial Profile

A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients with CLN2 Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cerliponase alfa (Primary) ; Cerliponase alfa (Primary)
  • Indications Neuronal ceroid lipofuscinosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BioMarin Pharmaceutical

    • Most Recent Events

    • 01 Jan 2024 Results from NCT01907087 and NCT02485899, determining the long-term safety and efficacy of intracerebroventricular cerliponase alfa in children with CLN2 disease, published in the Lancet Neurology
    • 09 Feb 2021 Status changed from active, no longer recruiting to completed.
    • 30 Jan 2021 This trial has been completed in Germany, according to European Clinical Trials Database record. (Global end date: 2020-12-10)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top